Biosynex SA (EPA:ALBIO)

Market Cap	15.94M -43.1%
Revenue (ttm)	97.95M -5.9%
Net Income	-70.99M
EPS	-4.82
Shares Out	18.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,850
Average Volume	6,699
Open	0.8460
Previous Close	0.8500
Day's Range	0.8420 - 0.8680
52-Week Range	0.4550 - 1.5900
Beta	0.81
RSI	50.38
Earnings Date	Apr 30, 2026

About Biosynex

Biosynex SA designs, manufactures, and distributes rapid diagnostic tests to patients and healthcare professionals in France and internationally. The company develops and markets IVDs in the form of RDTs and TRODs, immunoblot, molecular biology, and POC for screening, diagnosis, and prevention. It also provides thermometers, tensiometers, oximetry, hearing protection products, oral and dental hygiene products, self-tests, thermal pads, inhalation chambers, and thermotherapy products. The company was founded in 1993 and is based in Illkirch-Graf...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1993
• Employees: 454
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALBIO

Financial Performance

In 2024, Biosynex's revenue was 101.17 million, an increase of 8.81% compared to the previous year's 92.98 million. Losses were -43.33 million, 17.3% more than in 2023.